思創醫惠(300078.SZ)擬4725萬元轉讓參股子公司三創瑞海45%股權
格隆匯 12 月 22日丨思創醫惠(300078.SZ)公佈,公司於2020年12月22日召開第四屆董事會第二十四次會議,審議通過了《關於轉讓參股子公司股權的議案》,同意公司將持有的寧波三創瑞海投資管理有限公司(“三創瑞海”)45%股權轉讓給浙江三創投資管理有限公司(“浙江三創”),股權轉讓價格為4725萬元。
公司轉讓參股子公司三創瑞海45%股權,是基於三創瑞海經營現狀及發展前景的綜合考慮。此次股權轉讓有利於優化公司的資源配置,有利於維護公司整體利益及長遠利益。此次轉讓參股子公司部分股權不會對公司正常經營及財務狀況產生重大影響,不存在損害上市公司及股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.